Julie Hill

8.3k total citations · 2 hit papers
14 papers, 6.1k citations indexed

About

Julie Hill is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Julie Hill has authored 14 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in Julie Hill's work include HER2/EGFR in Cancer Research (8 papers), Gastric Cancer Management and Outcomes (8 papers) and Esophageal Cancer Research and Treatment (3 papers). Julie Hill is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Gastric Cancer Management and Outcomes (8 papers) and Esophageal Cancer Research and Treatment (3 papers). Julie Hill collaborates with scholars based in Switzerland, South Korea and China. Julie Hill's co-authors include Eric Van Cutsem, Michaela Lehle, Yung‐Jue Bang, Akira Sawaki, Yoon‐Koo Kang, A. Feyereislova, Florian Lordick, Josef Rüschoff, Hyun Cheol Chung and Atsushi Ohtsu and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and European Journal of Cancer.

In The Last Decade

Julie Hill

14 papers receiving 5.9k citations

Hit Papers

Trastuzumab in combinatio... 2010 2026 2015 2020 2010 2014 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    2010 5.3k citations Yung‐Jue Bang, Eric Van Cutsem et al. The Lancet profile →
  2. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
    2014 426 citations Eric Van Cutsem, Yung‐Jue Bang et al. Gastric Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julie Hill Switzerland 10 3.8k 3.5k 1.7k 1.2k 1.2k 14 6.1k
Yasushi Omuro Japan 18 4.0k 1.1× 4.0k 1.1× 1.8k 1.1× 1.3k 1.0× 1.3k 1.0× 56 6.7k
Michaela Lehle Switzerland 19 4.1k 1.1× 4.2k 1.2× 1.7k 1.0× 1.4k 1.1× 1.2k 1.0× 40 7.5k
Christopher R. Garrett United States 25 2.4k 0.6× 2.8k 0.8× 953 0.6× 1.4k 1.1× 1.1k 0.9× 50 5.3k
Jianming Xu China 33 3.0k 0.8× 3.8k 1.1× 1.5k 0.9× 1.1k 0.9× 854 0.7× 218 6.6k
Daniel V.T. Catenacci United States 37 2.9k 0.8× 4.1k 1.2× 2.8k 1.6× 1.5k 1.2× 634 0.5× 167 6.8k
В. А. Горбунова Russia 24 5.5k 1.4× 4.5k 1.3× 956 0.6× 2.3k 1.8× 435 0.4× 61 7.2k
J. Randolph Hecht United States 22 1.9k 0.5× 2.8k 0.8× 715 0.4× 949 0.8× 736 0.6× 78 4.2k
Oleg Lipatov Russia 28 4.6k 1.2× 4.7k 1.3× 758 0.4× 1.6k 1.3× 568 0.5× 79 6.9k
Petri Bono Finland 44 2.4k 0.6× 3.9k 1.1× 1.0k 0.6× 2.7k 2.2× 432 0.3× 156 7.5k
Hisato Kawakami Japan 32 1.6k 0.4× 2.7k 0.8× 631 0.4× 834 0.7× 271 0.2× 179 3.8k

Countries citing papers authored by Julie Hill

Since Specialization
Citations

This map shows the geographic impact of Julie Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Hill more than expected).

Fields of papers citing papers by Julie Hill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Hill. The network helps show where Julie Hill may publish in the future.

Co-authorship network of co-authors of Julie Hill

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Hill. A scholar is included among the top collaborators of Julie Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Hill. Julie Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Pathmanathan, Nirmala, Jingshu Geng, Wencai Li, et al.. (2016). Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: Results from a large, multicountry study. Asia-Pacific Journal of Clinical Oncology. 12(4). 369–379. 21 indexed citations
2.
Pathmanathan, Nirmala, Jingshu Geng, Wencai Li, et al.. (2016). Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study. Asia-Pacific Journal of Clinical Oncology. 13(3). 249–260. 9 indexed citations
3.
Satoh, Taroh, Yung‐Jue Bang, Evgeny Gotovkin, et al.. (2014). Quality of Life in the Trastuzumab for Gastric Cancer Trial. The Oncologist. 19(7). 712–719. 36 indexed citations
4.
Cutsem, Eric Van, Yung‐Jue Bang, Feng-yi Feng, et al.. (2014). HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 18(3). 476–484. 426 indexed citations breakdown →
5.
6.
Bang, Yung‐Jue, Eric Van Cutsem, A. Feyereislova, et al.. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 376(9742). 687–697. 5261 indexed citations breakdown →
7.
Cutsem, Eric Van, Yoon‐Koo Kang, Hyun Chul Chung, et al.. (2009). Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Journal of Clinical Oncology. 27(18_suppl). LBA4509–LBA4509. 69 indexed citations
8.
Cutsem, Eric Van, Yoon‐Koo Kang, Hyun Cheol Chung, et al.. (2009). Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Journal of Clinical Oncology. 27(15_suppl). LBA4509–LBA4509. 148 indexed citations
9.
Cutsem, Eric Van, Hyewon Chung, Lei Shen, et al.. (2009). Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Journal of Clinical Oncology. 27(18S). LBA4509–LBA4509. 24 indexed citations
10.
Macdonald, Peter S., Julie Hill, & Henry Krum. (2006). The Impact of Baseline HR and BP on the Tolerability of Carvedilol in the Elderly. American Journal of Cardiovascular Drugs. 6(6). 401–405. 3 indexed citations
11.
Bacus, Sarah, Julie Hill, & Neil L. Spector. (2006). Therapeutic implications for acquired resistance and heart toxicity using targeted therapy to erbB2. Journal of Clinical Oncology. 24(18_suppl). 3084–3084. 2 indexed citations
12.
Krum, Henry, Julie Hill, Friedrich Fruhwald, et al.. (2005). Tolerability of Beta-Blockers in Elderly Patients with Chronic Heart Failure: The COLA II Study. European Journal of Heart Failure. 8(3). 302–307. 52 indexed citations
13.
Speer, R. J., et al.. (1979). Combination chemotherapy of leukemia l1210 with platinum compounds and vitamins.. The Mouseion at the JAXlibrary (Jackson Laboratory). 235. 2 indexed citations
14.
Hill, Julie, et al.. (1961). Treatment of leukemia, lymphoma, and other malignant neoplasms with Vinblastine.. PubMed. 15. 41–61. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasushi Omuro Breakdown of academic impact, for papers by Michaela Lehle Breakdown of academic impact, for papers by Christopher R. Garrett Breakdown of academic impact, for papers by Jianming Xu Breakdown of academic impact, for papers by Daniel V.T. Catenacci Breakdown of academic impact, for papers by В. А. Горбунова Breakdown of academic impact, for papers by J. Randolph Hecht Breakdown of academic impact, for papers by Oleg Lipatov Breakdown of academic impact, for papers by Petri Bono Breakdown of academic impact, for papers by Hisato Kawakami
Rankless by CCL
2026